A Study of HS269 in Patients With Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
This is a Phase I, open-label, first in human study of HS269 tablet, a small molecule
highly-selective RET Inhibitor. The dose-escalation study will assess the safety,
tolerability, and pharmacokinetics of HS269 and determine the dose and schedule to be used in
Phase II. Seventeen to thirty-six patients with advanced solid tumor may be enrolled in this
study.